Read the 2003 Newsletters and recent scientific references 2003, issue 1: Deep Lumbar Neurons Control Ejaculation / by Truitt W / featuring SSP-SAP, Cat. #IT-11 SFN Poster of the Year SP-SAP as a Chronic Pain Therapeutic: An Update Targeting Talk: Custom Peptide-Saporin Conjugates Targeting Tools: Dermorphin-SAP (Cat. #IT-12) 2003, issue 2: Biotinylated targeting: A viable […]
Targeting Trends 2003 Newsletter Read More »
Advanced Targeting Systems announces the availability of two monoclonal antibodies to the dopamine transporter (DAT). These antibodies have become a standard for work on DAT and have already played a prominent role in the characterization of the dopamine transporter. The two antibodies are rat monoclonals, so they can be excellent for multiple staining protocols. Anti-DAT-NT, Cat.
Targeting Tools: Targeting the Dopamine Transporter Read More »
Substance P-Saporin (SP-SAP) is under development as a chronic pain therapeutic with tremendous potential to permanently eliminate suffering in many painful diseases and conditions. ATS is awaiting news from the National Institutes of Health on further funding to fulfill FDA requirements to bring SP-SAP to clinical trial in humans. ATS has a patent on SP-SAP
Substance P-Saporin (SP-SAP) Drug Development Update Read More »
Dopaminergic neurons are widely studied because of their role in one of the devastating diseases of old age, Parkinson’s. Lesioning studies using 6-hydroxydopamine or MPTP have been useful in research on Parkinson’s Disease. However, these reagents have limitations such as MPTP affecting catecholaminergic neurons and 6-OHDA stability and specificity issues. Targeting dopaminergic neurons with an
Cover Article: A New Immunotoxin for Targeting Dopaminergic Neurons Read More »